New pill takes on Hard-to-Treat prostate cancer in early human trial
Disease control
Recruiting now
This early-phase study is testing a new daily pill called ACE-232 in 67 men with metastatic castration-resistant prostate cancer that has stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see early signs of whether …
Phase 1 • Sponsor: Acerand Therapeutics (Hong Kong) Limited • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC